These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30705085)

  • 1. Progress in targeting RAS with small molecule drugs.
    McCormick F
    Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutation: from undruggable to druggable in cancer.
    Huang L; Guo Z; Wang F; Fu L
    Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate.
    Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA
    Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 9. KRAS
    Cagir A; Azmi AS
    Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS-targeted therapies in advanced solid cancers: drug the undruggable?
    Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
    Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378
    [No Abstract]   [Full Text] [Related]  

  • 12. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
    Yang A; Li M; Fang M
    Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
    [No Abstract]   [Full Text] [Related]  

  • 13. Undruggable KRAS-time to rebrand?
    The Lancet Oncology
    Lancet Oncol; 2021 Mar; 22(3):289. PubMed ID: 33662279
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
    Molina-Arcas M; Samani A; Downward J
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors of RAS proteins with oncogenic mutations.
    Orgován Z; Keserű GM
    Cancer Metastasis Rev; 2020 Dec; 39(4):1107-1126. PubMed ID: 32770300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.
    Schulze CJ; Seamon KJ; Zhao Y; Yang YC; Cregg J; Kim D; Tomlinson A; Choy TJ; Wang Z; Sang B; Pourfarjam Y; Lucas J; Cuevas-Navarro A; Ayala-Santos C; Vides A; Li C; Marquez A; Zhong M; Vemulapalli V; Weller C; Gould A; Whalen DM; Salvador A; Milin A; Saldajeno-Concar M; Dinglasan N; Chen A; Evans J; Knox JE; Koltun ES; Singh M; Nichols R; Wildes D; Gill AL; Smith JAM; Lito P
    Science; 2023 Aug; 381(6659):794-799. PubMed ID: 37590355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
    Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
    J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
    Hyun S; Shin D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugging "undruggable" genes for cancer treatment: Are we making progress?
    Duffy MJ; Crown J
    Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efforts to Develop KRAS Inhibitors.
    Holderfield M
    Cold Spring Harb Perspect Med; 2018 Jul; 8(7):. PubMed ID: 29101115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.